Q3 Earnings Alert! Plan early for this week’s stock reports with all key data in 1 placeSee list

Exclusive-Major Bayer shareholder Harris backs CEO's focus on internal restructuring

Published 07/03/2024, 13:16
Updated 07/03/2024, 22:01
© Reuters. FILE PHOTO: Logo of Bayer AG is pictured February 27, 2019. REUTERS/Wolfgang Rattay/File Photo
BAYGN
-

By Ludwig Burger

FRANKFURT (Reuters) -Major Bayer (ETR:BAYGN) shareholder Harris Associates on Thursday came out in strong support of the drugmaker's decision to suspend work on breaking up the diversified group, giving some breathing room to its embattled CEO.

The endorsement buoyed Bayer's shares, taking some pressure off Chief Executive Bill Anderson, who on Tuesday said he will pause for up to three years considerations to break apart the group to focus on problems including debt and litigation.

"Bill Anderson is absolutely taking the right path to enhance value creation at Bayer which will benefit all of Bayer’s stakeholders," said David Herro, vice chairman of one of Bayer's top three shareholders.

In a written response to a Reuters request for comment, Herro said the CEO was rightly focusing on efforts to "turn three very good businesses into great businesses".

Once this is accomplished, options in terms of corporate structure could be considered, he said. 

Investors were dubious about whether enough is being done to revive Bayer's fortunes and the shares plunged 8.5% on Tuesday after Anderson's comments.

Following Harris Associates' endorsement, Bayer shares pared earlier losses of as much as 6% on Thursday to trade 1.3% lower at 1515 GMT.

Anderson, who was hired last year to turn Bayer around, previously said he was examining options to separate, spin off or sell businesses. Reuters reported last month that no such action was on the cards for now with the CEO facing a multitude of problems, mostly stemming from the $63 billion takeover of Monsanto (NYSE:MON) in 2018.

These include U.S. litigation alleging harm from weed-killer glyphosate and other chemicals, weak agriculture markets and pressure from some investors to spin off or sell businesses.

While a development setback for Bayer's most promising experimental medicine late last year has further depressed the stock, the U.S. lawsuits have weighed the most. Bayer lost about two thirds of its value since the Monsanto takeover.

"Everything and anything possible must be done to minimize litigation payouts," Herro said on Thursday.

Bayer said this week it would vigorously defend itself against litigation, and also look for solutions "outside the courtroom". Anderson has declined to disclose details, saying this could give plaintiff lawyers an advantage.

Bayer won a case last week but its track record in court has been spotty. The company reached settlements for up to $9.6 billion in 2020 but failed to win approval for a proposal to handle future claims. It currently has $6.3 billion in provisions for more glyphosate payouts.

Herro also welcomed Bayer's nomination last week of three new supervisory board members, to be voted on at the April 26 annual shareholder meeting, which include Jeffrey Ubben, one of Wall Street's most prominent activist investors.

© Reuters. FILE PHOTO: Logo of Bayer AG is pictured February 27, 2019. REUTERS/Wolfgang Rattay/File Photo

The other two were biotechnology expert Nancy Simonian and former McKesson General Counsel Lori Schechter.

All there are "very strong individuals who will help the company move forward in a positive fashion," said Herro.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.